Rensselaer Polytechnic Institute President Shirley Ann Jackson was recognized by the Federal Bureau of Investigation (FBI) for her outstanding contributions to the community. FBI officials presented President Jackson with the FBI Albany Division’s 2020 Director’s Community Leadership Award at a ceremony on Tuesday.
TROY, N.Y. — A novel experiment aimed at studying the mechanics of amyloid fibrils — a type of protein aggregation associated with diseases like diabetes, Alzheimer’s, and Parkinson’s — started today aboard the International Space Station (ISS), led by a team at Rensselaer Polytechnic Institute.
Like many other cells and organs within the body, cardiac cells possess a type of asymmetry that may play an important role in healthy heart formation and could serve as the basis for interventions to prevent congenital heart defects.
An innovative testing platform that more closely mimics what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells. The platform, which uses a three-dimensional environment to more closely mirror a tumor microenvironment, is demonstrated in research published in Communications Biology.
A number of vulnerabilities, known collectively as deep learning adversaries, hold artificial intelligence (AI) back from its full potential in applications like improving medical imaging quality and computer-aided diagnosis.
More than two decades ago, Dr. Shirley Ann Jackson became the first African American woman to lead a top-ranked research university when she was named the 18th President of Rensselaer Polytechnic Institute. Today, President Jackson announced to the Rensselaer community that she intends to step down from her historic post in 2022.
A team including Rensselaer Polytechnic Institute researcher Gaetano Montelione has identified the design principles for creating large “ideal” proteins from scratch, paving the way for the design of proteins with new biochemical functions. The results were published today in Nature Communications.
Heart disease and cancer are the leading causes of death in the United States, and it’s increasingly understood that they share common risk factors, including tobacco use, diet, blood pressure, and obesity. Thus, a diagnostic tool that could screen for cardiovascular disease while a patient is already being screened for cancer has the potential to expedite a diagnosis, accelerate treatment, and improve patient outcomes.
Amir Hirsa, a professor of mechanical, aerospace, and nuclear engineering at Rensselaer Polytechnic Institute, has developed a device that could yield valuable insights about the fluid mechanics at play in diseases like diabetes, Alzheimer’s, and Parkinson’s.
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2, the virus that causes COVID-19.